[
    {
        "molecule_name": "Compounds of formula (I)",
        "protein_target_name": "norepinephrine transporter",
        "binding_metric": "Ki",
        "value": "<600",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences:\n\nCompounds of formula (I) and their pharmaceutically acceptable salts preferably exhibit a K<sub>i </sub>value less than 600 nM at the norepinephrine transporter as determined using the scintillation proximity assay described below.\nMore preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 100 nM at the norepinephrine transporter.\nMore preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 50 nM at the norepinephrine transporter.\nEspecially preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 20 nM at the norepinephrine transporter.\nAdvantageously, they have a reduced interaction (both as substrate and inhibitor) with the liver enzyme Cytochrome P450 (CYP2D6) and they preferably exhibit an IC50 of >6 μM according to the CYP2D6 inhibitor assay described below."
    },
    {
        "molecule_name": "Compounds of formula (I)",
        "protein_target_name": "norepinephrine transporter",
        "binding_metric": "Ki",
        "value": "<100",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences:\n\nCompounds of formula (I) and their pharmaceutically acceptable salts preferably exhibit a K<sub>i </sub>value less than 600 nM at the norepinephrine transporter as determined using the scintillation proximity assay described below.\nMore preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 100 nM at the norepinephrine transporter.\nMore preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 50 nM at the norepinephrine transporter.\nEspecially preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 20 nM at the norepinephrine transporter.\nAdvantageously, they have a reduced interaction (both as substrate and inhibitor) with the liver enzyme Cytochrome P450 (CYP2D6) and they preferably exhibit an IC50 of >6 μM according to the CYP2D6 inhibitor assay described below."
    },
    {
        "molecule_name": "Compounds of formula (I)",
        "protein_target_name": "norepinephrine transporter",
        "binding_metric": "Ki",
        "value": "<50",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences:\n\nCompounds of formula (I) and their pharmaceutically acceptable salts preferably exhibit a K<sub>i </sub>value less than 600 nM at the norepinephrine transporter as determined using the scintillation proximity assay described below.\nMore preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 100 nM at the norepinephrine transporter.\nMore preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 50 nM at the norepinephrine transporter.\nEspecially preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 20 nM at the norepinephrine transporter.\nAdvantageously, they have a reduced interaction (both as substrate and inhibitor) with the liver enzyme Cytochrome P450 (CYP2D6) and they preferably exhibit an IC50 of >6 μM according to the CYP2D6 inhibitor assay described below."
    },
    {
        "molecule_name": "Compounds of formula (I)",
        "protein_target_name": "norepinephrine transporter",
        "binding_metric": "Ki",
        "value": "<20",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences:\n\nCompounds of formula (I) and their pharmaceutically acceptable salts preferably exhibit a K<sub>i </sub>value less than 600 nM at the norepinephrine transporter as determined using the scintillation proximity assay described below.\nMore preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 100 nM at the norepinephrine transporter.\nMore preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 50 nM at the norepinephrine transporter.\nEspecially preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 20 nM at the norepinephrine transporter.\nAdvantageously, they have a reduced interaction (both as substrate and inhibitor) with the liver enzyme Cytochrome P450 (CYP2D6) and they preferably exhibit an IC50 of >6 μM according to the CYP2D6 inhibitor assay described below."
    },
    {
        "molecule_name": "Compounds of formula (I)",
        "protein_target_name": "Cytochrome P450 (CYP2D6)",
        "binding_metric": "IC50",
        "value": ">6",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences:\n\nCompounds of formula (I) and their pharmaceutically acceptable salts preferably exhibit a K<sub>i </sub>value less than 600 nM at the norepinephrine transporter as determined using the scintillation proximity assay described below.\nMore preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 100 nM at the norepinephrine transporter.\nMore preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 50 nM at the norepinephrine transporter.\nEspecially preferred compounds of formula (I) and their pharmaceutically acceptable salts exhibit a K<sub>i </sub>value less than 20 nM at the norepinephrine transporter.\nAdvantageously, they have a reduced interaction (both as substrate and inhibitor) with the liver enzyme Cytochrome P450 (CYP2D6) and they preferably exhibit an IC50 of >6 μM according to the CYP2D6 inhibitor assay described below."
    }
]